At Bantam Pharmaceutical, we are developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors.
Our mission is to destroy cancer cells from the inside, using our unique expertise to alter their inner mitochondrial dynamics.
Our lead candidate is BTM-3566, an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL).
Our Strategy
We are leveraging our science across two workstreams:
BTM-3566: We are progressing our lead candidate into the clinic
Discovery: We are uncovering other potential small molecules with applications in oncology
Our strategy will enable us to develop a pipeline of future indications in selected solid and hematological tumors, opening the door to new compounds and patient populations experiencing severe unmet need.
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
